Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan

We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]). Fem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine Journal 2017, Vol.64(5), pp.553-560
Hauptverfasser:	Onishi, Yukiko, Oura, Tomonori, Matsui, Akiko, Matsuura, Jun, Iwamoto, Noriyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Drug Therapy, Combination Dulaglutide Female Females GLP-1 receptor agonist Glucagon-Like Peptides - adverse effects Glucagon-Like Peptides - analogs & derivatives Glucagon-Like Peptides - therapeutic use Hemoglobin Humans Hypoglycemia Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Immunoglobulin Fc Fragments - adverse effects Immunoglobulin Fc Fragments - therapeutic use Insulin Insulin Glargine - adverse effects Insulin Glargine - therapeutic use Japan Liraglutide - adverse effects Liraglutide - therapeutic use Male Males Middle Aged Nausea Patients Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Safety Sex Sex Factors Sexes Studies Subgroup analysis Treatment Outcome Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!